<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite the advent of biological products, such as anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-Î± monoclonal antibodies (infliximab and adalimumab), for treatment of moderate to severe cases of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD), most patients depend upon aminosalicylates as the conventional treatment option </plain></SENT>
<SENT sid="1" pm="."><plain>In recent years, the increased knowledge of complex pathophysiological processes underlying IBD has resulted in development of a number of newer pharmaceutical agents like low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi>, <z:chebi fb="6" ids="25681">omega-3 fatty acids</z:chebi>, probiotics and innovative formulations such as high-dose, once-daily multi-matrix <z:chebi fb="0" ids="6775">mesalamine</z:chebi>, which are designed to minimize the inflammatory process through inhibition of different targets </plain></SENT>
<SENT sid="2" pm="."><plain>Optimization of delivery of existing drugs to the colon using the <z:chebi fb="0" ids="50266">prodrug</z:chebi> approach is another attractive alternative that has been utilized and commercialized for <z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi> (<z:chebi fb="37" ids="15365">ASA</z:chebi>) in the form of <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi>, balsalazide, olsalazine and ipsalazine, but rarely for its positional isomer 4-<z:chebi fb="37" ids="15365">ASA</z:chebi> - a well-established <z:chebi fb="0" ids="33231">antitubercular drug</z:chebi> that is twice as potent as <z:chebi fb="0" ids="6775">5-ASA</z:chebi> against IBD, and more specifically, <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The present review focuses on the complete profile of 4-<z:chebi fb="37" ids="15365">ASA</z:chebi> and its advantages over <z:chebi fb="0" ids="6775">5-ASA</z:chebi> and colon-targeting <z:chebi fb="0" ids="50266">prodrugs</z:chebi> reported so far for the management of IBD </plain></SENT>
<SENT sid="4" pm="."><plain>The review also emphasizes the need for reappraisal of this promising but unexplored entity as a potential treatment option for IBD </plain></SENT>
</text></document>